



The Nifty ended 0.12% up at 16,258.25. It opened on a flat note and remained choppy with a negative bias towards ending with another Spinning-top candle. Spinning-top implies consolidation. Chart pattern suggests Initial trading range is likely to be 16150-16350. However, bullish candle on the weekly suggests retracement towards critical supports may again find buyers. Next support below 16150 is placed around 16100 levels.

On the Nifty hourly chart, direction of the leading indicators suggests range-bound oscillation in the price band of 16150-16350.

Nifty patterns on multiple periods suggest; consolidation breakout in the previous week is a positive change from structural perspective. Hence, buy on dips is advised as long as critical supports are intact.

### Nifty Crucial Supports & Resistances-

**Supports- 16150, 16100 Resistances- 16350, 16400**

### Open Positional Calls-

T+3 Positional Buy-  
|Cash Segment| PETRONET on dips around @ 219-218, TGT- 226, SL- closing below 214

T+3 Positional Buy-  
|Cash Segment| AMARA RAJA on dips around @ 712-710, TGT- 750, SL- closing below 690

T+2 Positional Buy-  
|Cash Segment| GLENMARK on dips around @ 605-600, TGT- 640, SL- closing below 580

T+7 Positional Buy-  
|Cash Segment| CHENNAI PETRO on dips around @ 115-114, TGT- 124, SL- closing below 109

T+5 Positional Buy-  
|Cash Segment| SIEMENS on dips around @ 2030-2020, TGT- 2120, SL- closing below 1970

T+5 Positional Buy-  
|Cash Segment| RBL BANK on dips around @ 177-176, TGT- 186, SL- closing below 171

T+2 Positional Buy-  
|Cash Segment| HIND PETRO on dips around @ 267-266, TGT- 277, SL- closing below 261

T+7 Positional Sell-  
|Futures Segment| BHARTI AIRTEL Fut @ 603-605, TGT- 575, Closing SL- above 620

Key Contents	Page No.
Concall Update	4
Result Update	8
Domestic News	10

## Nifty Intraday Chart



## Market in Retrospect

India's key equity benchmarks edged higher, after swinging between gains and losses in the session with banking and I.T. stocks offsetting losses in metal and telecom stocks.

Nifty index ended 0.12% higher at 16,258.25. The broader markets represented by the NIFTY 500 Index ended 0.14% lower, ending at 13,935.05. Among the sectorial indices, NIFTY Media was the top gainer, gaining by 1.09%, followed by NIFTY Bank gaining by 0.61%. NIFTY metal was the top loser, losing by 1.87%.

M&M was the top gainer, gaining by 2.20%, followed by Axis Bank and Tech Mahindra gained by 1.98% & 1.81% respectively. Tata Consumer Products was the top loser, losing by 2.11%, followed by Coal India and Hindalco Industries which fell by 1.95% & 1.68% respectively.

The Advance : Decline ratio stood at 675:1366

### Market Turnover (In Crore) 09-08-2021

Name	Last	Previous
NSE Cash	57243.58	63604.40
NSE F&O	4145175.95	3142137.17
BSE Cash	5,991.62	4,789.98
BSE F&O	36.07	15.76

### FII Derivatives Flow (In Crore) 06-08-2021\*

Instrument	Purchase	Sale	Net
Index Future	2838.50	3427.01	588.51
Index Option	270595.55	271434.95	839.4
Stock Future	14330.69	15158.86	828.17
Stock Option	15111.78	15246.05	134.27

### Institutional Flow (In Crore) 06-08-2021\*

Institution	Purchase	Sale	Net
FII	6511.05	6580.42	69.37
DII	6439.14	7070.14	631

\*Data not updated till 6 PM

### NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
M&M	2.20	2.28	6700633	2815720
Axis Bank	1.98	4.76	6064688	7920625
Tech Mahindra	1.81	6.34	6585101	3322523
Bajaj Finserv	1.69	0.83	318865	235867
Cipla	1.36	0.26	3310964	4252811

### NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Bharti Airtel	1.42	6.03	9892910	29711820
Adani Ports & SE	1.52	1.14	7521213	12951490
Hindalco Industries	1.68	2.49	13778833	11007010
Coal India	1.95	0.45	12986298	7540415
Tata Con Products	2.11	0.70	1661739	4149313

### Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>  
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.asp>

## Sensex Intraday Chart



## Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	54402.85	125.13	0.23	2.74	3.85	10.56	43.01
Nifty	16258.25	20.05	0.12	2.35	3.62	9.68	44.98
BSE M Cap	22956.59	248.13	1.07	1.60	0.63	11.39	61.45
BSE S Cap	26611.67	194.30	0.72	1.70	2.85	19.77	94.69
Nifty MC 100	27742.50	203.20	0.73	1.80	1.31	13.02	72.28
BSE Auto	22936.90	41.48	0.18	0.67	1.36	4.01	34.13
BSE Capgoods	23588.05	194.35	0.82	0.84	2.73	14.44	81.80
BSE FMCG	13666.33	17.39	0.13	0.99	0.63	7.23	17.06
BSE Metal	20824.86	325.55	1.54	0.98	9.73	5.95	146.76
BSE Oil&Gas	15564.69	197.62	1.25	1.03	1.85	1.06	17.19
BSE Healthcare	26357.76	11.89	0.05	0.25	1.86	9.60	40.49
BSE Power	2650.26	21.84	0.82	0.87	2.11	3.42	71.29
BSE Realty	3194.05	25.15	0.78	4.31	9.61	30.66	98.85
BSE ConsDur	36455.27	123.59	0.34	1.10	1.99	15.34	65.18
BSE Bank	40993.51	262.25	0.64	4.15	3.34	9.27	65.99
BSE IT	31800.56	123.01	0.39	1.94	7.35	18.72	75.10

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.28	0.02	1.69	8.30	6.22	19.16	126.06
UK	0.57	0.04	6.06	10.17	12.37	25.94	312.95
Brazil	3.85	0.06	1.45	2.31	1.29	0.44	8.94
Japan	0.02	0.00	0.00	11.77	54.55	82.96	25.00
Australia	1.21	0.02	1.26	2.03	11.40	28.27	45.53
India	6.22	0.02	0.26	0.39	0.57	3.43	6.54
Switzerland	0.40	0.01	2.85	1.02	37.85	92.72	20.44
Germany	0.47	0.01	3.07	3.49	60.41	118.61	7.66

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.27	0.12	0.15	0.10	0.49	1.24	0.85
USD Index	92.81	0.01	0.01	0.83	0.74	2.86	0.67
YUAN	6.48	0.00	0.07	0.25	0.01	0.96	7.46
GBP	1.39	0.00	0.05	0.03	0.16	1.69	6.17
EUR	1.18	0.00	0.08	0.99	1.04	3.10	0.13
YEN	110.14	0.11	0.10	0.75	0.00	1.21	3.80

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	3371.00	5.00	0.15	2.40	2.15	5.91	124.58
Baltic Dirty	609.00	2.00	0.33	0.66	3.92	0.33	20.12
SG Dubai HY	1.39	0.13	10.32	256.41	162.26	36.27	208.89

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	35208.51	144.26	0.41	0.78	0.97	1.24	28.34
Nasdaq	14835.76	59.36	0.40	1.11	0.91	7.88	34.74
S&P 500	4436.52	7.42	0.17	0.94	1.53	4.82	32.38
FTSE100	7093.00	29.88	0.42	0.16	0.40	0.51	17.59
CAC40	6812.75	4.08	0.06	2.05	4.34	6.69	39.34
DAX	15734.07	27.09	0.17	1.06	0.30	2.17	24.14
Mexico IPC	51113.85	21.08	0.04	0.48	2.70	3.79	34.49
Brazil Bovespa	122810.4	1177.50	0.97	0.83	2.09	0.63	19.49
Russian RTS	1636.45	3.83	0.23	0.05	0.10	3.75	28.73
Japan Nikkei	27820.04	91.92	0.33	1.97	0.43	5.24	24.59
Hang Seng	26283.40	104.00	0.40	0.18	3.88	8.13	7.14
Taiwan Index	17485.15	41.13	0.23	0.10	1.00	1.16	36.30
Shanghai Comp	3494.64	36.41	1.05	0.88	0.84	2.22	4.19
KOSPI	3260.42	9.94	0.30	1.16	1.32	1.98	38.64
Malaysia KLCI	1496.73	6.93	0.47	0.25	1.57	5.71	5.16
Jakarta Comp	6127.46	75.98	1.22	0.51	1.45	3.36	19.12
Philippine SE	6632.57	92.66	1.42	2.89	2.96	5.97	13.45
Thai Exch	1540.19	18.47	1.21	0.99	0.77	2.83	16.29

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	65.59	2.69	3.94	7.96	12.03	1.06	59.12
BRENT Crude	68.04	2.66	3.76	6.65	8.96	1.25	43.42
Natural Gas	4.15	0.01	0.27	5.49	13.51	38.51	53.80

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1740.36	22.69	1.29	4.03	3.76	4.96	14.50
Silver(\$/Ounce)	23.79	0.55	2.24	6.40	8.89	13.35	15.96
Aluminium	2569.75	15.50	0.60	1.09	2.45	3.22	47.54
Copper	9446.00	25.51	0.27	2.63	1.78	6.43	45.78
Zinc	2974.75	44.75	1.48	1.77	1.98	1.54	24.03
Lead	2297.60	103.90	4.33	4.85	0.24	4.28	17.92

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	174.40	1.60	0.91	0.93	15.12	12.66	42.31
Cotton	91.02	0.68	0.74	1.55	3.77	4.75	45.17
Sugar	18.49	0.19	1.02	3.01	7.00	5.30	48.39
Wheat	713.50	5.50	0.76	2.19	16.02	6.40	35.00
Soybean	1334.75	2.00	0.15	1.39	0.41	6.89	50.78

### Amber Enterprises Ltd

#### Demand trend

Consumer durable industry witnessed a soft Q1FY22 due to second wave of Covid19. However, the impact was less severe this time due to regional lockdowns compared with nationwide lockdown last year. Company witnessed lower off-take during last 10 days of Apr-21 and during the month of May-June'21. However, demand recovery is faster than expected. The month of Jul-21 has seen positive growth in demand. There is not much Inventory in the channel compared to last year and it is at comfortable level. Company was successful in passing on commodity and forex increase during Q1FY22. Company maintained its market share at ~24% during Q1FY22.

#### Q1FY22 volume and realizations

RAC contributed ~64% to the revenues while Components share stood at ~36%. Company reported ~139% YoY growth in RAC volumes at 478k units due to low base last year. On QoQ, volume was down by ~59%. Compared to Q1FY20, volume was lower by ~54%. Company's gross margins have been improved both on YoY and QoQ basis at ~16.8%, as it was able to pass on price increase in the finished goods. Realizations during the quarter was up by ~19% YoY and ~15% QoQ at Rs 9,456/ unit due to high RM cost and increase in share of premium ACs.

#### PLI Scheme for RAC components

The Government main objective is to develop the component ecosystem in India and increase the domestic value addition in RAC manufacturing to ~75% from ~25% currently, over next 5-6 years. Company is all set to leverage this opportunity and this will help the company to strengthen its foothold in the domestic and exports market. Both the upcoming green field facilities will be covered under PLI scheme. Company to make PLI application for both Amber and subsidiary; Rs 3,000 mn capex will be for high value components and Rs 500-1,000 mn capex will be towards mid to low value components. Company is expected to manufacture 6 out of 10 components like Sheet metal, PCBs boards, Motors, Injection moulding, Heat exchanges, cross flow fans under PLI scheme. Other components are Copper and aluminium tube, compressors and service vaults. Currently, ~67% of electronics parts, ~60% of the Cross flow and copper and aluminium tubes is being imported. Heat exchanger, Sheet metal is outsourced to domestic manufacturers.

#### Capex

A major chunk of the ongoing capex of ~Rs 4,000 mn towards 2 new plants, i.e. Rs 3,500 mn will be done in the current FY22, while ~Rs 1,000 mn will be spent in FY23. Apart from that, there will be additional capex of Rs 1,000 mn in PICL for motors, which will be spent over next 5 years. Company's installed capacity for RAC is currently at 4.5 mn units. Post the commencement of 2 new plants, the capacity will be increased by ~44% to 6.5 mn by FY23 end.

### Added 6 new customers

Import ban on refrigerant filled ACs has opened opportunity for domestic manufacturers. Between Oct-20 to Mar-21, the imports have been come down by ~85%. Company has signed 6 new customers for gas charging facilities since notification came in Oct-20. Out of that, 4 customers have been converted for manufacturing. Company expect incremental volume of 800-1000 units from new customers.

### Export opportunity

Company is in discussion with large brands for Middle East and US markets. The approval process for Middle East market is completed and Company has started exports of RACs and components to Bahrain. Going forward, it expects a growth of ~30-40% for the Middle-East market. For US markets, approval is on track and it is expected to receive by next year. US is the big market for RAC as it imports ~19-20 mn units annually from China (~75%) and Thailand (~25%).

### SIDWAL

Q1FY22 revenue stood up by ~66% YoY at Rs 500 mn; EBITDA margins at ~24.6%. Company is confident to deliver and maintain healthy order book ahead; Q1FY22 Order book stood at ~Rs 4,250 mn. Progressing well with new product development, like Dumper AC for Mining machine used in Defence, Electric AC for Electric bus, AC for Harvester Combine, Metro AC for different climate conditions in India for Mumbai metro, Delhi metro and Bangalore metro.

### PICL

Q1FY22 revenue stood at Rs 360 mn; EBITDA margins at ~9%. In India, ~70% of the BLDC motors are being imported, which provides big opportunity for the company. Company has done the R&D and required capex for BLDC motors and work has already been started. It is in advance stages with few large OEMs for this product. Company expect to double its revenues from PICL along with margin expansion over the next 2 years, due to increase in product offering and ability to cater domestic and exports market in more meaningful way.

### ILJIN & EVER

ILJIN's Q1FY22 revenue stood at Rs 430 mn; EBITDA loss at Rs 17 mn. EVER's revenue stood at Rs 180 mn; EBITDA margin at ~0.8%. Added 5 new customers in ILJIN for in-house developed Inverter PCBs for RAC; few more customers are in process of approval. As the market is moving towards Inverter ACs, company is confident of growing its revenue from ILJIN and EVER. Company is expecting good growth for ILJIN & EVER in 9M FY22.

### Ready for new BEE rating

Company is ready for new BEE energy ratings to be applicable from 01-Jan-22. New ratings will enhance the costing by Rs 700-1200 depending on model.

### On competition

In India, ~40%-45% of domestic RAC manufacturing is being outsourced; out of that Amber's share is ~70%. According to Frost and Sullivan, domestic outsourcing is expected to increase to ~52% by FY23. Don't see new capacities coming in OEM category as threat as Amber is currently ~97% ODM.

### Outlook

Domestic market size for RAC is estimated at ~5.2 mn in FY21 compared with ~7 mn in FY20. FY22 domestic market volume is expected to be ~6-6.2 mn. Over next 8-9 years, domestic RAC market size is estimated to be ~24 mn, exports number is estimated to be ~10 mn units, which means ~35-40 mn units are expected to be manufactured in India.

## Narayana Hrudayalaya Ltd

### Q1FY22 Performance

Operations in India, i.e., elective procedures in Q1FY22 were impacted because of the second wave of Covid, however, there were no idle days per se and the impact was not as severe as was witnessed in Q1FY21, besides the queue of Covid patients was also high enough to provide a steady revenue stream during the quarter. All these along with the superb performance of the Cayman facility resulted in the highest ever quarterly revenue for Narayana. Highest ever quarterly PAT was also recorded in Q1FY22.

### **Covid-19 contributed to 23.8% of India revenue during Q1FY22.**

The flagship facility at Bangalore, RTIICS was impacted by a high degree in Q1FY22 as the centre witnessed a 44% de-growth in revenue.

### Cayman Operations

As Cayman operations are performing very well, the **original estimate of debt financing of the new facility at Cayman, which was roughly USD 50 million will get trimmed although the Management was hesitant to guide on an absolute figure. Part of the borrowing will hit the balance sheet 6 months down the line progressively building on for the next six months. After 12 months, another tranche would be borrowed.**

While there was a bit of cyclicity in the Cayman revenue contributing an uptick for the quarter owing to the fact that there was a good spend out of the insurance packages prevailing in the island (benefits from these usually taper down during October to December), Narayana has also invested in the clinics and in departments such as urology and medical oncology, which resulted in increased revenues. **Going forward, Narayana plans to chase topline growth by making more such investments and may also sacrifice few percentage points of margin in order to ensure topline growth.** Two clinics are operational in Cayman now. Three more would be opened in the next two years. An investment of c. USD 1 million is required in each of these clinics.

While the borders have opened in Cayman, not many patients have flocked to the US for treatment as was the earlier expectation. Thus, the stickiness in revenue from local patients is welcoming and it is expected that this stickiness would continue as local patients are happy with the quality of treatment and the convenience.

**Narayana wants a more diversified revenue from Caribbean countries and towards this effect it is in talks with various countries like Bermuda and Jamaica.** It is already advising a hospital in St. Lucia on a management contract basis. Narayana may also pursue O&M contracts in Caribbean going forward.

Dividend income from the Cayman subsidiary would be received by the parent company in the next two quarters.

**Narayana is also keen on expanding in Bangladesh on O&M contracts basis.**

**While the total operational beds in Cayman as of now is between 95-100 out of a total of 110 capacity beds, a large number of these would cease to exist once the new facility in Cayman comes up. The space freed by these beds would be used for daycare, OPD, diagnostic areas, etc.**

### India Operations

**Narayana has envisioned a plan for the refurbishment and reorganisation of its Indian hospitals in the next five years. There would be a transformation plan for the hospital beds particularly in general wards. A portion of the current space occupied by general wards would get allotted to more critical care and ICU beds, daycare rooms and diagnostic capabilities given that these are more important areas of today's treatment necessities. 20% of the hospital space would still continue to get occupied by general wards. While high end beds would also get introduced, Narayana would in no way move away from its proposition of providing quality medical care at affordable prices as that is its core ethos and thus Narayana would continue to be within the accessibility of a vast majority of middle class Indians. Concessional RBI loans would help Narayana in its five year plan.**

Organic and inorganic capex are planned for Kolkata. There would also be capacity addition in Mysore and Raipur. There are plans of opening clinics in Bangalore, Gurugram and Kolkata. Capex, north of Rs 2500 million would be incurred for India in FY22. There would be an upward bias towards the normalised capex amount that is proposed to be incurred beyond FY22.

While a lot of investment has been made in the back end with respect to technology, which resulted in improving efficiency of the hospitals, commensurate investments have not been made in the customer facing front end. **Narayana recognises this and has plans of improving the front-end vastly within the next one year.** Investments in front-end would be replicated in Cayman as well. Telemedicine has really opened new doors for Narayana as people from Central India and South India (ex-Karnataka) have started accessing Narayana's telemedicine facilities. These regions did not feature majorly in Narayana's revenue streams in the last few years.

July and August to date have seen very high revenues across all Narayana facilities. In fact, Narayana has recorded its highest monthly revenue in July.

### AstraZeneca Pharma

AstraZeneca Pharma India reported a 45.03 per cent decline in its net profit to Rs 10.24 crore for the June ended quarter. The company had posted a net profit of Rs 18.63 crore for the corresponding period of the previous fiscal. Revenue from operations stood at Rs 175.40 crore for the quarter under consideration. It was Rs 193.57 crore for the same period a year ago. The company's board of directors has declared an interim dividend of Rs 2 per equity share for the financial year 2021-22.

### Balrampur Chini Mills

Net profit of Balrampur Chini Mills declined 44.69% to Rs 76.93 crore in the quarter ended June 2021 as against Rs 139.09 crore during the previous quarter ended June 2020. Sales declined 20.27% to Rs 1140.44 crore in the quarter ended June 2021 as against Rs 1430.34 crore during the previous quarter ended June 2020.

### Chemcon Speciality Chemicals

Net profit of Chemcon Speciality Chemicals rose 51.70% to Rs 13.41 crore in the quarter ended June 2021 as against Rs 8.84 crore during the previous quarter ended June 2020. Sales rose 25.27% to Rs 57.21 crore in the quarter ended June 2021 as against Rs 45.67 crore during the previous quarter ended June 2020.

### IFB Agro

IFB Agro reported standalone quarterly numbers, Net Sales at Rs 546.76 crore in March 2021 up 27.1% from Rs. 430.18 crore in March 2020. Quarterly Net Profit at Rs. 14.41 crore in March 2021 up 2768.02% from Rs. 0.54 crore in March 2020. EBITDA stands at Rs. 20.47 crore in March 2021 up 1724.6% from Rs. 1.26 crore in March 2020. IFB Agro EPS has increased to Rs. 15.38 in March 2021 from Rs. 0.58 in March 2020.

### Shankara Building Products

Net profit of Shankara Building Products reported to Rs 6.26 crore in the quarter ended June 2021 as against net loss of Rs 25.30 crore during the previous quarter ended June 2020. Sales rose 28.74% to Rs 445.53 crore in the quarter ended June 2021 as against Rs 346.07 crore during the previous quarter ended June 2020.

### Subex

Net profit of Subex declined 11.08% to Rs 13.48 crore in the quarter ended June 2021 as against Rs 15.16 crore during the previous quarter ended June 2020. Sales declined 9.13% to Rs 80.60 crore in the quarter ended June 2021 as against Rs 88.70 crore during the previous quarter ended June 2020.



### **Kirloskar Industries**

Net profit of Kirloskar Industries reported to Rs 72.73 crore in the quarter ended June 2021 as against net loss of Rs 7.43 crore during the previous quarter ended June 2020. Sales rose 283.88% to Rs 824.26 crore in the quarter ended June 2021 as against Rs 214.72 crore during the previous quarter ended June 2020.

### **Igarashi Motors India**

Net profit of Igarashi Motors India reported to Rs 3.75 crore in the quarter ended June 2021 as against net loss of Rs 10.52 crore during the previous quarter ended June 2020. Sales rose 226.06% to Rs 148.39 crore in the quarter ended June 2021 as against Rs 45.51 crore during the previous quarter ended June 2020.

### **WPIL**

Net profit of WPIL rose 16.51% to Rs 8.89 crore in the quarter ended June 2021 as against Rs 7.63 crore during the previous quarter ended June 2020. Sales rose 9.79% to Rs 62.34 crore in the quarter ended June 2021 as against Rs 56.78 crore during the previous quarter ended June 2020.

### **Hero Electric sells over 15,000 high speed electric vehicles in first half of 2021**

Electric two-wheeler maker Hero Electric on Monday reported sales of over 15,000 high-speed two-wheelers in the first half of the year. The company had sold 3,270 units in the first half of last year amid disruptions due to the outbreak of coronavirus pandemic. Hero Electric also said after the second wave of COVID-19, it witnessed recovery with sales of over 4,500 high-speed electric two-wheelers in July this year as compared to 399 units in the same month last year. The company has already announced plans to expand its existing facility to manufacture over 3 lakh EVs per year to meet demand and grow 100 per cent over last year.

### **Amara Raja Batteries plans \$1 billion capex in 5-7 years, to focus more on new-age energy storage systems**

Amara Raja Batteries plans to invest about USD one billion in the next five to seven years towards capex to be spent for both organic and inorganic growth. The battery maker would be focusing more on the new-age energy storage systems such as Lithium-ion Technology keeping in view the market trends as Lead Acid battery market growth rate is expected to taper off over a period of time. So we are talking about a close to USD one billion investments for a 10 to 12 Gigawatt hours (Lithium-ion battery) facility under the ACC(Advanced Chemistry Cell) PLI (Production Linked Incentives) Scheme of the government. The time period for execution is dependent on the market demand growth, but we foresee that this investment could happen over a period of 5 to 7 years. Amamra Raja has been making about Rs 400 to Rs 500 crore investment on capex and sustaining the existing businesses traditionally every year. Replying to a query, he said the Amara Raja is expecting 15 to 17 per cent growth in revenues in the next five years and hoped that it would become a USD two billion entity by then.

### **Zydus Cadila likely to get emergency use approval for its COVID vaccine this week**

Zydus Cadila's three-dose COVID-19 vaccine ZyCoV-D is expected to get an emergency-use nod from the expert committee this week. The government expects that in October-November, four more Indian pharmaceutical companies will start production of indigenous vaccines that will help to meet the domestic demand, Biological E and Novartis vaccines will also be available in the market in the coming days, while Zydus Cadila will soon get an emergency use nod from Expert Committee. The EUA is expected to be given for adults first, though the Drug Controller General of India (DCGI) had earlier asked the Ahmedabad-based firm to return with more data on its ZyCoV-D.

### CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Honeywell Automation India Ltd	Cash dividend of INR85 effective 10-08-2021
IIFL Wealth Management Ltd	Cash dividend of INR35 effective 10-08-2021
ICICI Securities Ltd	Cash dividend of INR13.50 effective 10-08-2021
Golkunda Diamonds & Jewelry Ltd	Cash dividend of INR1.20 effective 10-08-2021
Godrej Agrovet Ltd	Corporate meeting effective 10-08-2021
GE Power India Ltd	Corporate meeting effective 10-08-2021
Kirloskar Industries Ltd	Corporate meeting effective 10-08-2021
Symphony Ltd	Corporate meeting effective 10-08-2021
RS Software India Ltd	Corporate meeting effective 10-08-2021
Automotive Axles Ltd	Corporate meeting effective 10-08-2021
SH Kelkar & Co Ltd	Corporate meeting effective 10-08-2021
IDBI Bank Ltd	Corporate meeting effective 10-08-2021
Central Bank of India	Corporate meeting effective 10-08-2021
ICICI Lombard General Insurance Co Ltd	Corporate meeting effective 10-08-2021

### Domestic Events

- **Upcoming Result's:-** 3I Infotech, Aditya Spinners, Ahluwalia Contracts, Alchemist Corporation, Amtek Auto, Ashoka Buildcon, Asian Hotels, Bal Pharma, Balaji Telefilms, Balmer Lawrie Investments, Century Plyboards, Coal India, Cochin Shipyard, Deepak Fertilisers & Petrochemicals Corporation, Eveready Industries India, Godrej Agrovet, Huhtamaki India, India Glycols, Ion Exchange, Jindal Hotels, Jindal Steel & Power, Kiri Industries, Linde India, Lupin, Manappuram Finance, Meghmani Organics, Motherson Sumi Systems, Muthoot Capital Services, Nath Bio-Genes, Reliance Infrastructure, Siemens, Simplex Trading & Agencies, Spencers Retail ,Titagarh Wagons, Tourism Finance Corporation Of India, Trent, V-Mart Retail, Whirlpool Of India, Zomato

### Global Events

- Euro Area ZEW Economic Sentiment Index for August 2021.
- Japan Current Account Balance for June 2021.

### **Analyst Certification:**

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

**Sudipto Datta, Compliance Officer**

**SMIFS Limited.**

**Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.**

**Contact No.: +91 33 4011 5414 /91 33 6634 5414**

**Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)**

**Website: [www.smifs.com](http://www.smifs.com)**